23:13 , Jan 25, 2018 |  BC Innovations  |  Strategy

Takeda rides Denali’s ATV

In its deal with Denali, Takeda has not only boosted its CNS pipeline, but also gained access to a delivery technology that could open the door to a host of CNS targets only druggable with...
18:43 , Jul 6, 2017 |  BC Week In Review  |  Clinical News

Takeda submits Japanese NDA for rasagiline to treat PD

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) submitted an NDA in Japan for Azilect rasagiline mesylate (TVP-1012) to treat Parkinson’s disease (PD). The product is an irreversible selective inhibitor of monoamine oxidase B (MAO-B) . In 2014,...
08:00 , Dec 14, 2015 |  BioCentury  |  Strategy

Networking in Japan

Teva Pharmaceutical Industries Ltd. has been trying to capitalize on growth in Japan's generics market since the government set out to drive generics utilization in 2007, but the company's first attempt at a Japanese JV...
00:53 , Aug 4, 2015 |  BC Extra  |  Company News

Teva buying majority stake in Immuneering

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) will acquire a 51% stake in computational genomic analysis company Immuneering Corp. (Cambridge, Mass.). Teva spokesperson Denise Bradley said Teva will pay Immunoneering $45 million in three tranches, and will...
08:00 , Nov 10, 2014 |  BioCentury  |  Finance

Convert resurgence

Biotechs have raised $5.6 billion through convertible debt financings so far this year, the highest amount since 2006. Two bankers attributed the resurgence to a growing mid-cap space that is taking advantage of low interest...
07:00 , Aug 11, 2014 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Biodefense company Emergent BioSolutions Inc. (NYSE:EBS) was up $0.44 to $22.47 last week after submitting a BLA to FDA for Anthrax immune globulin IV (AIGIV) to treat inhaled anthrax. AIGIV is being developed...
07:00 , Aug 7, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Neurology; Parkinson's disease (PD) Monoamine oxidase B (MAO-B) In vitro studies have identified indazole carboxamide-based MAO-B inhibitors that could help treat PD and other neurological...
07:00 , Jun 30, 2014 |  BC Week In Review  |  Clinical News

Azilect rasagiline regulatory update

FDA approved an sNDA for Azilect rasagiline to include use as an adjunct to dopamine agonists to treat Parkinson’s disease. The irreversible selective inhibitor of monoamine oxidase B (MAO-B) is already marketed to treat PD...
07:00 , May 12, 2014 |  BioCentury  |  Finance

Zeroing in on immunity

Investors in Anokion S.A. 's CHF33 million ($37.6 million) series A round think the company's antigen-specific approach to inducing immune tolerance will lead to less immunogenic formulations of existing cancer and hematology drugs, as well...
07:00 , May 5, 2014 |  BC Week In Review  |  Company News

Teva, Takeda deal

Teva granted Takeda exclusive, Japanese rights to develop and commercialize rasagiline, which is approved as Azilect in more than 40 countries for Parkinson's disease (PD). Takeda will be responsible for developing rasagiline for the Japanese...